drugset / Trial / NCT00960245

Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions

NCT00960245

Phase 1 Completed 34 enrolled Sandoz
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to demonstrate the relative bioavailability of Nadolol (1 x 80 mg) tablets under fasting conditions.

Timeline

Start
1994-07
Primary completion
1994-07
Completion
1994-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Corgard Unknown 80 mg
Subject Nadolol Unknown 80 mg